Where is the Akston cat GLP-1 trial?

The Cornell University College of Veterinary Medicine in Ithaca, New York. The trial enrolls 70 cats with the option to expand to 140.

How does AKS-562c differ from Okava's OKV-119?

AKS-562c is a novel GLP-1 Fc-fusion delivered as weekly injections. OKV-119 is an exenatide-releasing implant lasting roughly 6 months. Different molecules, different delivery formats.

When will AKS-562c be available?

Trial readout remains expected Q2-Q3 2026. Treatment phase completed approximately mid-February 2026; as of May 19, 2026, ~14 weeks of post-treatment silence have elapsed — beyond the typical data-analysis window for a trial of this size. Akston's IPO roadshow is now confirmed active (S-1/A amendment #30 + Free Writing Prospectus filed mid-May 2026); no AKS-562c clinical data appeared in those filings, meaning the data is still in analysis as of mid-May. Readout most likely arrives via 8-K after IPO pricing. FDA submission timeline depends on results. Realistic earliest commercial launch for cats: 2028-2029.

Has the Cornell trial finished yet?

The treatment phase of the primary cohort most likely concluded in mid-February 2026, based on the announced ~11-week observation window from the November 25, 2025 trial initiation. As of May 19, 2026 — roughly 14 weeks post-treatment-phase completion — Akston has not publicly announced a readout, and no 8-K or S-1/A amendment covering AKS-562c clinical results has been filed with the SEC. The IPO roadshow is now confirmed active (S-1/A #30 + FWP, mid-May 2026); that amendment contained no AKS-562c data, confirming the data was not yet known to management as of that filing.

Is Akston Biosciences a public company?

Akston Biosciences (AXTN, NYSE American) filed an S-1 in early May 2026 for a $20M IPO at approximately $100M market cap. As of mid-May 2026 the company has filed S-1/A amendment #30 and a Free Writing Prospectus, confirming the IPO roadshow is actively underway with underwriter ThinkEquity. The offering is expected to price in late May 2026. Once priced, Akston becomes a fully public company subject to SEC quarterly disclosure requirements; future AKS-562c updates will surface in 8-K filings.

What do the S-1/A amendment #30 and Free Writing Prospectus filings mean?

Akston filed S-1/A amendment #30 and a companion Free Writing Prospectus simultaneously in mid-May 2026. This paired filing pattern is the standard SEC sequence that confirms an IPO roadshow is actively underway — institutional investor meetings are in progress with underwriter ThinkEquity. Importantly, the amendment contained no new AKS-562c clinical trial data. Under SEC rules, material clinical results would have been required in the amendment if known at time of filing. Their absence confirms the Cornell data had not reached management as of mid-May 2026. Pricing is expected in late May 2026; AKS-562c results will most likely surface via 8-K filing after the IPO closes.

AKS-701d is Akston Biosciences' lead clinical program — a veterinary biologic for canine bladder cancer. It's separate from AKS-562c (the cat GLP-1 candidate) and is the primary commercial focus per the S-1 filing.

Akston Biosciences IPO + AKS-562c Cornell Trial Watch (2026)

Akston Biosciences' 11-week Cornell feline trial treatment phase completed approximately mid-February 2026. As of May 19, 2026 — ~14 weeks of post-treatment silence — no readout has been announced. New development: Akston filed S-1/A amendment #30 plus a Free Writing Prospectus in mid-May 2026, confirming the IPO roadshow is now actively underway. No AKS-562c clinical data appeared in the amendment. We're tracking the roadshow, the silence, and what comes next.

Status — May 19, 2026 · ~14 weeks post-treatment, no readout, IPO roadshow activeCornell AKS-562c treatment phase completed approximately mid-February 2026 — roughly 11 weeks after the November 25, 2025 trial start. As of May 19, 2026, ~14 weeks (~3.5 months) have elapsed since treatment-phase completion with no public readout from Akston or Cornell. New: Akston filed S-1/A amendment #30 and a Free Writing Prospectus (FWP) in mid-May 2026, confirming the IPO roadshow is now actively underway. The S-1/A amendment does not contain new AKS-562c clinical trial data — under SEC rules, material trial results would be required if they were known at time of filing, so their absence means the data is still in analysis or not yet available to management. No 8-K covering AKS-562c clinical results has been filed. We continue monitoring AXTN EDGAR filings, Cornell press releases, and veterinary trade press.

Update — May 2, 2026 · Akston files S-1 IPOAkston Biosciences filed an S-1 for a $20M IPO at approximately $100M market capitalization, listing under ticker AXTN on NYSE American. The filing makes Akston a public company with mandatory financial disclosure — a meaningful credibility signal for the Cornell AKS-562c cat GLP-1 trial. The S-1 lists AKS-701d (canine bladder cancer) as the lead product and AKS-562c (cat GLP-1) in the disclosed pipeline. Cornell trial results remain unpublished.

Update — Mid-May 2026 · S-1/A Amendment #30 + Free Writing Prospectus — Roadshow Confirmed ActiveAkston filed S-1/A amendment #30 and a companion Free Writing Prospectus (FWP) simultaneously in mid-May 2026 — the standard SEC filing pair that confirms an IPO roadshow is actively underway (institutional investor meetings are in progress). This is a significant milestone: the roadshow proceeding means Akston and underwriter ThinkEquity believe the offering is marketable at the $8-10/share range. Critically: the S-1/A amendment does not contain new AKS-562c clinical trial data. Under SEC Regulation S-K and Staff guidance, any material development — including trial results — must be disclosed in an S-1/A if the information is known at time of filing. The absence of AKS-562c data in amendment #30 means one of two things: (a) the Cornell data is still in analysis as of mid-May 2026, or (b) analysis is complete but results are not yet sufficient to constitute a material event requiring disclosure. Either way, no public readout is imminent from the SEC channel as of this update. The most likely path to AKS-562c disclosure is now a post-pricing 8-K, once the IPO is complete and the forced-amendment window closes.

SEC Disclosure Watch — Roadshow Now LiveWith the roadshow confirmed active (S-1/A #30 + FWP filed mid-May 2026), the SEC forced-disclosure mechanism has entered its final phase. If AKS-562c trial results become known during the roadshow — before pricing — Akston must halt the offering and file a supplemental S-1/A before resuming investor meetings; they cannot price with a materially incomplete prospectus. Once the offering prices and closes, that window shifts to 8-K disclosure. Watch AXTN's SEC EDGAR filings for any last-minute S-1/A (pre-pricing) or 8-K (post-pricing). The roadshow typically runs 1-2 weeks; pricing could come as early as late May 2026.

Readout Watch — Cornell TrialTrial initiated November 25, 2025. With an ~11-week primary observation period, treatment-phase completion was approximately mid-February 2026. As of May 19, 2026, ~14 weeks have elapsed since treatment completion — beyond the outer edge of the typical 8-14 week data-analysis-to-disclosure range for a trial of this size. The IPO roadshow now actively underway (S-1/A #30 + FWP, mid-May 2026) introduces a hard deadline: if results are known before IPO pricing (likely late May 2026), they must appear in a last-minute S-1/A; if known post-pricing, via 8-K. A late-May or Q3 2026 readout — via 8-K — is the most probable path. If no readout emerges by late Q3 2026, the field will start asking harder questions about cohort performance. We're monitoring AXTN EDGAR filings, Cornell research announcements, and dvm360 / Veterinary Practice News.

Akston Biosciences is a Beverly, Massachusetts-based biotechnology company developing protein-based therapeutics for both human and veterinary applications. As of May 2026, Akston is a publicly listed company (AXTN, NYSE American) following an S-1 IPO filing for ~$20M at approximately $100M valuation. They are one of two companies currently running cat GLP-1 trials. Their candidate, AKS-562c, is a once-weekly GLP-1 Fc-fusion injection being studied at the Cornell University College of Veterinary Medicine. Trial initiation was announced November 2025.

AXTN Stock — What to Know

Ticker: AXTN. Exchange: NYSE American. Listing date: May 2, 2026. Akston Biosciences listed as a small-cap biotech with a market capitalization of approximately $100M and a $20M IPO raise. As of publication, AXTN is a thinly-traded micro-cap — typical for vet-pharma at this stage — and exposure carries the standard small-cap biotech risk profile (clinical trial outcomes, single-asset concentration risk on lead AKS-701d, regulatory uncertainty for both pipeline programs).

Watch for these material events in 8-K filings or press releases:

•Cornell AKS-562c trial readout (Q2-Q3 2026) — material event likely triggering pre-announcement and 8-K filing.
•FDA pre-submission meetings for AKS-562c if trial succeeds — would surface 6-12 months before IND/NADA filing.
•AKS-701d (canine bladder cancer) updates — the lead asset, larger commercial impact than AKS-562c.
•Follow-on financing — a $20M IPO is small; Akston will likely raise additional capital within 12-18 months. Trial success drives valuation for next round.

Editorial noteGLP-1 Pets is not a financial advice site. We surface AXTN information because Akston's public-company status changes how readers should evaluate the AKS-562c story (mandatory disclosure, pre-announcement timing, etc.). For investment decisions, consult a financial advisor and read Akston's SEC filings directly at SEC EDGAR.

Why the IPO Filing Matters

Going public meaningfully changes how readers should evaluate the AKS-562c story. Pre-IPO, Akston disclosed trial details voluntarily — useful but uncorroborated. Post-IPO:

•Mandatory financial disclosure — Akston now reports to the SEC quarterly. Trial spending, R&D budget allocation across AKS-701d (lead) and AKS-562c (pipeline), and any material clinical updates surface in 10-Q filings.
•Pipeline transparency — The S-1 explicitly lists AKS-562c as a disclosed pipeline asset. Hiding bad news becomes legally risky; investors will read every quarterly letter for trial progress.
•Timeline visibility — Public companies typically pre-announce material readouts to manage market reaction. Watch for AXTN press releases and 8-K filings around the Q2-Q3 2026 readout window.
•Capital constraint — A $20M raise is small for biotech. Akston needs trial wins to justify follow-on rounds. The Cornell readout has heightened commercial significance for them.

Akston Pipeline Beyond AKS-562c

Asset	Indication	Stage	Notes
AKS-701d	Canine bladder cancer	Lead clinical program	Akston's lead vet asset per S-1. Different drug class from AKS-562c.
AKS-562c	Cat obesity (GLP-1)	Cornell trial — readout pending	Once-weekly Fc-fusion injection. 70 cats enrolled.
Other vet candidates	Various	Preclinical	S-1 lists earlier-stage protein-engineering programs without specific timelines.

Knowing AKS-701d is the lead program changes how to read trial-readout signals: if AKS-562c data is mixed, Akston still has a primary commercial path through bladder cancer. The downside risk for AKS-562c shareholders is therefore narrower than for a single-asset company — but the upside if both succeed is correspondingly larger.

What Is AKS-562c?

AKS-562c is a GLP-1 receptor agonist fused to an Fc fragment — a protein engineering technique that extends drug half-life by binding to FcRn receptors that recycle proteins through the body. The same Fc-fusion approach is used in human-side drugs like dulaglutide (Trulicity). Fc-fusion typically gives once-weekly to once-monthly dosing.

Cornell Trial Design

Element	Detail
Sponsor	Akston Biosciences
Site	Cornell University College of Veterinary Medicine
Drug	AKS-562c (GLP-1 Fc-fusion, weekly injection)
Target species	Domestic cats (overweight or obese)
Cats enrolled	70 (option to expand to 140)
Primary observation	~11 weeks
Trial start	November 25, 2025
Treatment-phase completion (est.)	~Mid-February 2026 (11 weeks post-start)
Post-completion silence (as of May 19, 2026)	~14 weeks — no public readout; S-1/A #30 + FWP filed mid-May (roadshow active, no AKS-562c data in amendment)
Expected readout	Q2-Q3 2026 (window narrowing; IPO/legal timing adds complexity)

What to Watch For in the Readout

When Akston reports results, the field will read the data along five axes. We'll publish a full breakdown the day the news drops — but here's the framework we'll apply:

Body weight change at 11 weeks vs control. Human-side GLP-1s deliver 5-15% weight loss in similar timeframes. A clinically meaningful feline result will likely cluster in the 4-10% range — anything above 10% is a strong signal; below 3% would be commercially marginal.
Body Condition Score (BCS) shift. The 9-point scale is the veterinary efficacy gold standard. A meaningful trial moves the average BCS from 7-8 down toward 5-6.
Adverse event profile. Watch closely for hepatic enzyme elevations (ALT, ALP) — feline rapid weight loss carries hepatic lipidosis risk that human GLP-1 trials don't face. Vomiting and decreased appetite are expected; severity and discontinuation rates matter.
Injection site tolerability. Weekly subcutaneous injections in cats face owner-compliance friction. The trial likely tracks injection-site reactions, owner-reported handling difficulty, and dropouts attributable to injection burden.
Cohort expansion decision. Akston announced a 70-cat trial with the option to expand to 140. If they expand, that's a confidence signal. If they don't, it could mean the primary cohort answered the question definitively (good sign) or fell short (bad sign).

Three Outcomes, Three Field Responses

Scenario	What it means for the field
Strong efficacy + clean safety	Akston files for FDA approval H2 2026. Cat GLP-1 commercial launch realistic late 2027 / early 2028. Dog trial starts likely announced within 6 months. Veterinary pharma incumbents (Zoetis, Boehringer, Elanco, Merck Animal Health) accelerate their own programs.
Modest efficacy or safety questions	Akston runs a confirmatory trial. FDA path stretches to 2028-2029. Field watches Okava's MEOW-1 readout (summer 2026) as the deciding signal — if Okava also shows modest results, GLP-1-for-cats becomes a question of whether the regulatory pathway justifies the commercial opportunity.
Trial fails or significant safety concern	AKS-562c program likely shelved or pivoted. Field resets to Okava's OKV-119 (MEOW-1 trial) as the only remaining feline GLP-1 candidate. Dog programs at both companies likely delayed. Investor confidence in the entire pet GLP-1 category takes a hit.

How AKS-562c Compares to OKV-119

Attribute	Akston AKS-562c	Okava OKV-119
Active molecule	Novel GLP-1 Fc-fusion	Exenatide (existing GLP-1)
Delivery	Weekly subcutaneous injection	6-month subcutaneous implant
Trial site	Cornell University Vet College	Multi-site veterinary network
Trial cats	70 (expandable to 140)	≥50
Trial start	November 2025	December 2025
Primary observation	~11 weeks	3 months + 3 mo opt
Expected readout	Q2-Q3 2026	Summer 2026
Repeat dosing	Weekly forever	Every 6 months

Get the readout the day it dropsWe're tracking Akston Biosciences' investor channels, Cornell press releases, and trade press (dvm360, Veterinary Practice News). Join the trial alerts list and we'll send one email when the AKS-562c results are public.

Akston AKS-562c — Cornell Trial Readout Watch